



September 23, 2025

To,
Listing/ Compliance Department
BSE LTD.
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

SCRIP CODE: 543748

To,
Listing/ Compliance Department
**National Stock Exchange of
India Limited**
"Exchange Plaza", Plot No. C/1,
G Block, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
SYMBOL: AARTIPHARM

Dear Sir/Madam,

Sub: Investor Presentation
Ref: Regulation 30 of the SEBI (LODR)
Regulations 2015

Please find enclosed herewith presentation made to the Shareholders of the Company at the **6th Annual General Meeting** held on Monday, September 22, 2025.

Please take the same on your records.

Thanking you,

Yours faithfully,
For AARTI PHARMALABS LIMITED

Jeevan Mondkar
COMPANY SECRETARY AND LEGAL HEAD
ICSI M. NO. A22565

Encl. a/a.

AARTI PHARMALABS LIMITED

www.aartipharmalabs.com | CIN : L24100GJ2019PLC110964 | Email : info@aartipharmalabs.com


Admin Office : 204, Udyog Kshetra, 2nd Floor, Mulund - Goregaon Link Road, Mulund (W), Mumbai, PIN - 400 080, Maharashtra, INDIA, T : +91 22 67976666 | F : +91 22 25653234
Regd. Office : Plot No. 22-C/1 & 22-C/2, 1st Phase, G.I.D.C., Vapi 396 195, District - Valsad, Gujarat, INDIA, T : +91 260 2400467, +91 99099 94655



6th Annual General Meeting

SEP 2025

25 Years of Pharmaceutical Excellence



220+

Products

58

Patents Filed



500+

Global Clients


50+

Export Countries



3

State-of-the-art
R&D facilities



6

Manufacturing
Units


3

USFDA Units



2,100+

Employees



50

US DMF

31

CEP




15-20%

Global
Market Share
in Xanthine



0.19x

Net Debt/Equity



A+

Credit rating



COMPANY OVERVIEW



- Aarti Pharmalabs Limited (APL) is part of the Aarti group – a diversified chemical conglomerate with group turnover of INR 130+ bn (FY25)
- Globally recognized manufacturer of generic API, Xanthine derivatives and a leading player in CDMO/CMO services
- Demonstrated strong expertise in development of robust & cost-effective process for rapid scale up and commercial production
- Received accreditation from several agencies, including USFDA, EU GMP, EDQM (European Pharmacopoeia), KFDA (Korea), and COFEPRIS (Mexico)
- Strategically located in western India with proximity to ports

HIGHLIGHTS



One of the leading small molecule CDMO/CMO company in India.




Regulatory focussed operations with expertise in novel chemistries;




Largest manufacturer of Xanthine Derivatives in India

STANDALONE REVENUE (INR Mn)
& EBITDA MARGINS (%)



GEOGRAPHICAL SALES (FY25)




KEY MILESTONES



KEY BUSINESS SEGMENTS

QUARTERLY REVENUE BREAK-UP



ANNUAL CONSOLIDATED INCOME STATEMENT

PARTICULARS (INR Mn)	FY25	FY24	Y-O-Y
Operational Revenue	21,151	18,526	14.2%
Operating Expenses	16,507	14,666	12.6%
EBITDA	4,644	3,860	20.3%
EBITDA Margin (%)	21.96%	20.84%	112 Bps
Depreciation and Amortisation	869	732	18.7%
Finance costs	269	172	56.4%
Other Income	101	49	NA
PBT	3,607	3,005	20.0%
Tax Expense	883	836	5.6%
PAT	2,724	2,169	25.6%
PAT Margin (%)	12.88%	11.71%	117 Bps
Other Comprehensive Income	(98)	(4)	NA
Total Comprehensive Income	2,626	2,165	21.3%
Diluted EPS	30.04	23.93	25.5%

HISTORICAL CONSOLIDATED INCOME STATEMENT

PARTICULARS (INR Mn)	9M-FY22	FY23	FY24	FY25
Operational Revenue	11,999	19,452	18,526	21,151
Total Expenses	9,929	16,031	14,666	16,507
EBITDA	2,070	3,421	3,860	4,644
EBITDA Margins (%)	17.25%	17.59%	20.84%	21.96%
Depreciation and Amortisation	421	625	732	869
Finance costs	120	211	172	269
Other Income	25	23	49	101
PBT	1,554	2,608	3,005	3,607
Tax	331	673	836	883
PAT	1,223	1,935	2,169	2,724
PAT Margins (%)	10.19%	9.95%	11.71%	12.88%
Other Comprehensive Income	70	(35)	(4)	(98)
Total Comprehensive Income	1,293	1,900	2,165	2,626
Diluted EPS (INR)	13.49	21.35	23.93	30.04

ANNUAL STANDALONE INCOME STATEMENT

PARTICULARS (INR Mn)	FY25	FY24	Y-O-Y
Operational Revenue	17,714	15,021	17.9%
Operating Expenses	13,449	11,560	16.3%
EBITDA	4,265	3,461	23.2%
EBITDA Margin (%)	24.08%	23.04%	104 Bps
Depreciation and Amortisation	791	660	19.8%
Finance costs	256	166	54.2%
Other Income	145	110	31.8%
PBT	3,363	2,745	22.5%
Tax Expense	790	738	7.0%
PAT	2,573	2,007	28.2%
PAT Margin (%)	14.53%	13.36%	117 Bps
Other Comprehensive Income	(51)	1	NA
Total Comprehensive Income	2,522	2,008	25.6%
Diluted EPS	28.38	22.14	28.2%


HISTORICAL STANDALONE INCOME STATEMENT

PARTICULARS (INR Mn)	9M-FY22	FY23	FY24	FY25
Operational Revenue	9,410	15,112	15,021	17,714
Total Expenses	7,613	12,028	11,560	13,449
EBITDA	1,797	3,084	3,461	4,265
<i>EBITDA Margins (%)</i>	<i>19.10%</i>	<i>20.41%</i>	<i>23.04%</i>	<i>24.08%</i>
Depreciation and Amortisation	372	558	660	791
Finance costs	113	205	166	256
Other Income	25	13	110	145
PBT	1,337	2,334	2,745	3,363
Tax	270	617	738	790
PAT	1,067	1,717	2,007	2,573
<i>PAT Margins (%)</i>	<i>11.34%</i>	<i>11.36%</i>	<i>13.36%</i>	<i>14.53%</i>
Other Comprehensive Income	71	(7)	1	(51)
Total Comprehensive Income	1,138	1,710	2,008	2,522
Diluted EPS (INR)	11.78	18.95	22.14	28.38


CONSOLIDATED FINANCIAL HIGHLIGHTS




OPERATIONAL INCOME (INR Mn)




EBITDA (INR Mn) & EBITDA MARGINS (%)




PAT (INR Mn) & PAT MARGINS (%)



Net Debt to Equity (X)



ROCE (%) & ROE (%)





THANK YOU

AARTI PHARMALABS LIMITED